Recent Trends in Prostate Cancer Incidence by Age, Cancer Stage, and Grade, the United States, 2001–2007

Abstract

Objective. To examine prostate cancer trends by demographic and tumor characteristics because a comprehensive examination of recent prostate cancer incidence rates is lacking. Patients and Methods. We described prostate cancer incidence rates and trends using the 2001–2007 National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program data (representing over 93% of US population). Because of coding changes in cancer grade, we restricted analysis to 2004–2007. We conducted descriptive and trend analyses using SEER∗Stat. Results. The overall prostate cancer incidence rate was stable from 2001 to 2007; however, rates significantly increased among men aged 40–49 years (APC = 3.0) and decreased among men aged 70–79 years (APC = 2.3), and 80 years or older (APC = −4.4). About 42% of localized prostate cancers diagnosed from 2004 to 2007 were poorly differentiated. The incidence of poorly differentiated cancer significantly increased among localized (APC = 8.0) and regional stage (APC = 6.1) prostate cancers during 2004–2007. Conclusions. The recent trend in prostate cancer incidence was stable but varied dramatically by age. Given the large proportion of poorly differentiated disease among localized prostate cancers and its increasing trend in more recent years, continued monitoring of prostate cancer incidence and trends by demographic and tumor characteristics is warranted.

Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995–2012

“…However, most studies focused on the impact of the 2008 USPSTF guidelines. Moreover, we found only one study that comprehensively evaluated stagespecific cancer incidence trends, but data were available only through 2007 (24). Therefore, we used the most recent (April 23, 2015) NCI SEER program data to evaluate age-and stagespecific trends in prostate cancer incidence from 1995 through 2012 (3).…”

Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activityin vitroandin vivo

“…Prostate cancer (PCa) is the most frequently diagnosed cancer and the sixth leading cause of cancer-related death in males; and PCa rates are 2-5 times higher in developed countries compared with developing countries (Jemal et al, 2011;Li et al, 2012). Based on the NCCN guidelines for PCa, docetaxel (DTX) is the standard chemotherapy and the only treatment demonstrated to increase overall survival for advanced PCa (Berthold et al, 2008;Hoang et al, 2014).…”

Treatment of elderly patients with advanced urological cancer

“…There is evidence that in the USA and Europe only a minority of elderly prostate cancer patients with localized cancer (which comprise 80 % of all cases) receive curative therapy [53][54][55].…”